Literature DB >> 23637091

Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009.

Maryam M Asgari1, Jashin J Wu, Joel M Gelfand, Craig Salman, Jeffrey R Curtis, Leslie R Harrold, Lisa J Herrinton.   

Abstract

BACKGROUND: Few population-based studies have reported the prevalence of psoriatic disease.
OBJECTIVE: We validated computerized diagnoses to estimate the prevalence of psoriasis and psoriatic arthritis.
METHOD: We identified adults with ≥1 ICD-9 diagnosis codes of 696.0 (psoriatic arthritis) or 696.1 (psoriasis) in clinical encounter data during 1996-2009 and used chart review to confirm the diagnoses in random samples of patients. We then used the best performing case-finding algorithms to estimate the point prevalence of psoriasis and psoriatic arthritis.
RESULTS: The number of persons with a diagnosis for psoriasis (ICD-9 code 696.1) was 87 827. Chart review of a random sample of 101 cases with at least one dermatologist-rendered psoriasis code revealed a positive predictive value (PPV) of 90% (95% CI, 83-95) with sensitivity of 88% (95% CI, 80-93). Psoriatic arthritis (code 696.0) was recorded for 5187 patients, with the best performing algorithm requiring ≥2 diagnoses recorded by a rheumatologist or ≥1 diagnosis recorded by a rheumatologist together with ≥1 psoriasis diagnoses recorded by a dermatologist; the PPV was 80% (95% CI, 70-88) with sensitivity 73% (95% CI, 63-82). Among KPNC adults, the point prevalence of psoriasis, with or without psoriatic arthritis, was 939 (95% CI, 765-1142) per 100 000, and the overall prevalence of psoriatic arthritis, with or without psoriasis, was 68 (95% CI, 54-84) per 100 000.
CONCLUSION: Within an integrated health care delivery system, the use of computerized diagnoses rendered by relevant disease specialists is a valid method for identifying individuals with psoriatic disease.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  computerized medical information; epidemiology; incidence, prevalence, health maintenance organizations; pharmacoepidemiology; psoriasis; psoriatic arthritis

Mesh:

Year:  2013        PMID: 23637091      PMCID: PMC3720770          DOI: 10.1002/pds.3447

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  31 in total

Review 1.  Psoriasis.

Authors:  Michael P Schön; W-Henning Boehncke
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

2.  Prevalence and treatment of psoriasis in the United Kingdom: a population-based study.

Authors:  Joel M Gelfand; Rachel Weinstein; Steven B Porter; Andrea L Neimann; Jesse A Berlin; David J Margolis
Journal:  Arch Dermatol       Date:  2005-12

3.  Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants.

Authors:  X T Lima; R Minnillo; J M Spencer; A B Kimball
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-04-04       Impact factor: 6.166

4.  Epidemiology of psoriatic arthritis in the population of the United States.

Authors:  Joel M Gelfand; Dafna D Gladman; Philip J Mease; Nana Smith; David J Margolis; Tamar Nijsten; Robert S Stern; Steven R Feldman; Tara Rolstad
Journal:  J Am Acad Dermatol       Date:  2005-10       Impact factor: 11.527

5.  Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002.

Authors:  Don Robinson; Monica Hackett; John Wong; Alexa B Kimball; Russell Cohen; Mohan Bala
Journal:  Curr Med Res Opin       Date:  2006-05       Impact factor: 2.580

Review 6.  Psoriatic arthritis: epidemiology, clinical features, course, and outcome.

Authors:  D D Gladman; C Antoni; P Mease; D O Clegg; P Nash
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

7.  The prevalence of psoriasis in African Americans: results from a population-based study.

Authors:  Joel M Gelfand; Robert S Stern; Tamar Nijsten; Steven R Feldman; John Thomas; Joe Kist; Tara Rolstad; David J Margolis
Journal:  J Am Acad Dermatol       Date:  2005-01       Impact factor: 11.527

8.  Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.

Authors:  Robert S Stern; Tamar Nijsten; Steven R Feldman; David J Margolis; Tara Rolstad
Journal:  J Investig Dermatol Symp Proc       Date:  2004-03

9.  Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

Authors:  J Koo
Journal:  Dermatol Clin       Date:  1996-07       Impact factor: 3.478

10.  Incidence and risk factors for psoriasis in the general population.

Authors:  Consuelo Huerta; Elena Rivero; Luis A García Rodríguez
Journal:  Arch Dermatol       Date:  2007-12
View more
  34 in total

Review 1.  The Epidemiology of Psoriatic Arthritis.

Authors:  Alexis Ogdie; Pamela Weiss
Journal:  Rheum Dis Clin North Am       Date:  2015-09-11       Impact factor: 2.670

Review 2.  Disease burden and treatment challenges of psoriatic arthritis in Africa and the Middle East.

Authors:  Mohamed Bedaiwi; Ibrahim A Al-Homood; Ayman El-Garf; Imad Uthman; Nancy Sunna; Reenad Nassier; Haytham Mohamed; Jamal Al Saleh
Journal:  Rheumatol Int       Date:  2019-05-27       Impact factor: 2.631

3.  Validation of Autism Spectrum Disorder Diagnoses in Large Healthcare Systems with Electronic Medical Records.

Authors:  Karen J Coleman; Marta A Lutsky; Vincent Yau; Yinge Qian; Magdalena E Pomichowski; Phillip M Crawford; Frances L Lynch; Jeanne M Madden; Ashli Owen-Smith; John A Pearson; Kathryn A Pearson; Donna Rusinak; Virginia P Quinn; Lisa A Croen
Journal:  J Autism Dev Disord       Date:  2015-07

4.  Differential Associations of Chronic Inflammatory Diseases With Incident Heart Failure.

Authors:  Sameer Prasada; Adovich Rivera; Arvind Nishtala; Anna E Pawlowski; Arjun Sinha; Joshua D Bundy; Simran A Chadha; Faraz S Ahmad; Sadiya S Khan; Chad Achenbach; Frank J Palella; Rosalind Ramsey-Goldman; Yvonne C Lee; Jonathan I Silverberg; Babafemi O Taiwo; Sanjiv J Shah; Donald M Lloyd-Jones; Matthew J Feinstein
Journal:  JACC Heart Fail       Date:  2020-04-08       Impact factor: 12.035

5.  Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA.

Authors:  Joseph F Merola; Vivian Herrera; Jacqueline B Palmer
Journal:  Clin Rheumatol       Date:  2018-07-26       Impact factor: 2.980

6.  Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.

Authors:  Michael D George; Joshua F Baker; Jesse Yenchih Hsu; Qufei Wu; Fenglong Xie; Lang Chen; Huifeng Yun; Jeffrey R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-11-02       Impact factor: 4.794

7.  Comparative Overall Comorbidity Burden Among Patients With Hidradenitis Suppurativa.

Authors:  Sarah Reddy; Andrew Strunk; Amit Garg
Journal:  JAMA Dermatol       Date:  2019-07-01       Impact factor: 10.282

8.  Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.

Authors:  Huifeng Yun; Shuo Yang; Lang Chen; Fenglong Xie; Kevin Winthrop; John W Baddley; Kenneth G Saag; Jasvinder Singh; Jeffrey R Curtis
Journal:  Arthritis Rheumatol       Date:  2016-09       Impact factor: 10.995

9.  The Detection of Rheumatic Disease through Hospital Diagnoses with Examples of Rheumatoid Arthritis and Giant Cell Arteritis: What Are We Missing?

Authors:  C John Michet; Cynthia S Crowson; Sara J Achenbach; Eric L Matteson
Journal:  J Rheumatol       Date:  2015-08-01       Impact factor: 4.666

10.  Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis.

Authors:  J J Wu; L Liu; M M Asgari; J R Curtis; L Harrold; C Salman; L J Herrinton
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-11-07       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.